In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ENSURE-AF trial Edoxoban: a New Anticoagulant Option Before Cardioversion

Atrial Fibrillation

Rome, Italy – 30 Aug. 2016: Patients with atrial fibrillation (AF) who need anticoagulation before undergoing electrical correction of their abnormal heartbeat (cardioversion) may benefit from treatment with edoxoban - a non-vitamin K antagonist (VKA) oral anticoagulant (NOAC), according to results of the ENSURE-AF trial.

Edoxaban is “an effective and safe alternative”to standard therapy, which uses VKAs, said investigator Andreas Goette, MD, from St. Vincenz-Hospital, Paderborn, Germany, who presented the Hot Line results at ESC Congress 2016, with simultaneous publication in The Lancet.

While VKA anticoagulation works well, it has a major limitation in that it requires regular monitoring and dose adjustment to ensure that patients reach anticoagulation targets, explained Prof Goette. This can sometimes delay cardioversion for several weeks.

“At a practical level, our study results show that newly diagnosed non-anticoagulated AF patients can start edoxaban as early as two hours prior to their cardioversion procedure if they have access to transoesophageal echocardiography (TEE) or 3 weeks prior without.”

Edoxaban was previously shown to be safe and effective compared to standard VKA therapy (enoxaparin/warfarin) among patients with AF in the ENGAGE AF-TIMI 48 study, but the impact of electrical cardioversion was not systematically assessed in that study.

ENSURE-AF, the largest randomised clinical trial of anticoagulation for cardioversion in patients with AF, “provides the largest prospective trial data for a NOAC in this clinical setting,” noted Prof Goette. “Results suggest that edoxaban is an effective and safe alternative to standard enoxaparin/warfarin, a VKA therapy.”

The phase 3b study, involving 239 study sites in 19 countries in Europe and the United States, included 2,199 patients with documented non-valvular AF who were scheduled for electrical cardioversion after anticoagulation therapy.

A total of 1,095 patients were randomised to receive edoxaban, while the remaining 1,104 received enoxaparin/warfarin (dosing varied depending on patient characteristics).

Of these 988 (90·2%) and 966 (87·5%) patients, respectively, were cardioverted either electrically or spontaneously, some with the use of transoesophageal echocardiography (TEE).

The primary efficacy objective of this study was to compare the incidences of the composite endpoint of stroke, systemic embolic event (SEE), myocardial infarction (MI) and cardiovascular (CV) death between the two groups at day 28 (ITT analysis).

This endpoint occurred at a comparable rate in both groups: 0·5% patients in the edoxaban arm vs. 1·0% in the enoxaparin/warfarin arm (OR=0·46; 95% CI, 0·12–1·43)

The primary safety outcome was a composite endpoint of major and clinically relevant non-major (CRNM) bleeding events at 30 days.

This also occurred at a comparable rate 1·5%and 1·0% respectively (OR=1·48; 95% CI, 0·64–3·55).

In short, “edoxaban had similar rates of major bleeding and thromboembolism compared to well-managed, optimized enoxaparin/warfarin therapy. The results were similar whether TEE-guidance was used or not, whether patients had received prior anticoagulation or not, and in patients with a broad range of associated comorbidities.”


Notes to editor

Sources of funding: The study was funded by Daiichi Sankyo.

Disclosures: Professor Goette has served as a consultant for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer, and a speaker for Astra Zeneca, Bayer, Berlin Chemie, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Pfizer, and Sanofi-Aventis.

ESC Press Office
For background information, please contact the ESC Press Office.

For press enquiries, please contact, the Media & Press Coordinator, Jacques Olivier Costa: +393427028575 

For independent comment on site, please contact the ESC Spokesperson coordinator, Celine Colas: +393402405148 

The press conference timetable is available here. 

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2016

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2016. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.